| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
24004 |
| Drug |
Dostarlimab |
| Brand |
Jemperli® |
| Indication |
Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. |
| Rapid review commissioned |
02/02/2024 |
| Rapid review completed |
09/02/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/02/2024 |
| Pre-submission consultation with Applicant |
09/04/2024 |
| Full submission received from Applicant |
22/08/2024 |
